Summary: In 162 adults with below-knee diabetic foot ulcers, a double-blinded RCT found that adding wound blotting-guided biofilm management to standard care improved the composite DMIST wound score at week 3 (p<0.01) and increased biofilm removal at weeks 1 (p=0.01) and 2 (p=0.03) over a short three-week course. The trial measured wound-assessment and biofilm surrogates rather than complete healing or amputation.
PICO Summary
| Element | Detail |
|---|---|
| Population | 162 adults with diabetes and a below-knee diabetic foot ulcer of at least two weeks’ duration; single outpatient clinic, Indonesia; double-blinded RCT. |
| Intervention | Standard of care plus wound blotting-guided biofilm management (additional cleansing directed by the blotting result and antimicrobial dressing), applied weekly for three weeks. |
| Comparison | Standard of care alone followed by application of any appropriate dressing, applied weekly for three weeks. |
| Outcome | Significant between-group difference in total DMIST wound-assessment score at week 3 (p<0.01); significantly greater biofilm percentage reduction at week 1 (p=0.01) and week 2 (p=0.03). Effect sizes, 95% confidence intervals, ARR and NNT were not reported in the abstract; complete healing and amputation were not primary endpoints. |
Biofilm-guided care for diabetic foot ulcers
Double-blind RCT · below-knee DFU · 3 weeks
Adding wound blotting-guided biofilm management to standard care significantly improved the composite DMIST wound score at 3 weeks and biofilm removal at weeks 1 and 2. Endpoints are surrogates, not healing or amputation, so a longer confirmatory trial is needed.
Expert Commentary
This double-blinded randomised trial offers an encouraging early signal that targeting wound biofilm, guided by an inexpensive wound blotting test, can accelerate measurable wound improvement in diabetic foot ulcers. Blinding and randomisation lend it credibility above the usual wound-care literature, and the consistency of the biofilm-reduction signal at weeks 1 and 2 alongside a better composite DMIST score at week 3 is internally coherent. The findings should be read with restraint. The endpoints are surrogate wound-assessment and biofilm metrics, not complete closure, time-to-healing or amputation, and the intervention ran for only three weeks at a single Indonesian centre, so durability and generalisability remain unknown. The principal limitation is this short horizon: a composite score that moves at three weeks may or may not translate into ulcers that actually close, which is why the authors themselves call for a twelve-week confirmatory trial. No effect sizes or confidence intervals were available in the abstract, so the magnitude of benefit cannot yet be judged. Can I use this with my patients? Not yet as routine practice, though clinicians already using wound blotting may reasonably fold biofilm-directed cleansing into a structured DFU pathway while awaiting longer data. A larger, multicentre trial reporting healing and limb outcomes is needed before this changes standard care.
References
Astrada A, Nakagami G, Kashiwabara K, Sanada H. Biofilm detection-based wound management in diabetic foot ulcers: a randomised controlled trial. J Wound Care. 2025;34(7):514-524. doi:10.12968/jowc.2024.0051